The stock of Applied Therapeutics Inc. (NASDAQ:APLT) increased by $0.55 on Tuesday to finish at $2.53, up 27.78 percent. The last five days have seen an average of 1,907,080 shares of common stock traded. 12 times new highs were reached in the current year, with a gain of $1.7700. The average number of shares traded over the last 20 days was 1,207,755, while the average volume over the last 50 days totaled 673,120.
APLT stock appreciated 76.92% since last month. On 09/05/23, the company’s shares reached a one-month low of $1.2200. The stock touched a high of $2.18 on 09/19/23, after rallying from a low of $0.50 in 52 weeks. The price of APLT stock has risen by 232.89% or $1.7700 this year, reaching a new high 12 times. Still, the stock price is up 16.06% from the 52-week high.
Insider Transactions
APLT stock investors should be aware that Applied Therapeutics Inc. (APLT) stock had its last reported insider trading activity 252 days ago on Jan 11. On Jan 11, President and CEO Shendelman Shoshana sold 15,870 shares at $0.91 each. This transaction resulted in the insider making $14,442. On Jan 11, Perfetti Riccardo sold 6,053 shares at a price of US$0.91. After the transaction, the insider now owns 154,856 shares. Chief Commercial Officer Hansard Adam had earlier sold 4,495 shares on Jan 11 for $0.91 a share. The transaction was completed for $4,090.
Financial Health
For the three months ended June 29, Applied Therapeutics Inc.’s quick ratio was 0.90, while its current ratio was 0.90, indicating its inability to pay off its debt.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. APLT’s return on assets (ROA) during the last 12 months has been -173.70%.
Earnings Surprise
According to Applied Therapeutics Inc.’s quarterly financial report for the quarter that ended June 29. It was predicted that Applied Therapeutics Inc.’s quarterly earnings would be -$0.37, but it ended up being -$0.26, beating the consensus by -42.30%. EBITDA was -$16.49 million for the quarter. At the end of Applied Therapeutics Inc.’s most recent quarter ended June 29, its liabilities totaled 47.98 million, while its total debt was $1.9 million. Equity owned by shareholders amounts to $63.12 million.
Technical Picture
Here’s a quick look at Applied Therapeutics Inc.’s (APLT) price momentum from a technical perspective. As of 19 September, the RSI 9-day stood at 82.67%, suggesting the stock is Overbought, with a 152.80% historical volatility rate.
The stochastic %K and %D were 90.29% and 79.55% respectively, while the average true range (ATR) was 0.2400. Based on the 14-day stochastic reading of 97.04%, the RSI (14) reading is 76.45%. On the 9-day MACD Oscillator, the stock is at 0.3200, and the 14-day reading is at 0.4600.
Analyst Ratings
Applied Therapeutics Inc. (NASDAQ: APLT) was downgraded by Barclays to a an Equal weight rating in its latest research report. The stock was previously rated as a an Overweight. Analysts have assigned Applied Therapeutics Inc. (APLT) an Buy rating. APLT is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 1 rate it overweight and 2 others recommend it as a buy.
What is APLT’s price target for the next 12 months?
The current consensus forecast for the stock is between $4.00 and $14.00, with a median target price of $5.00. In analyzing these forecasts, the average price target given by analysts for Applied Therapeutics Inc. (APLT) is $7.67.
